Clinical trials: Repigmentation
Vitiligo
Evaluation of AMG 714 for Vitiligo
This study is designed to evaluate the efficacy of AMG 714 for the treatment of adult participants with vitiligo.
- Trial name
- REVEAL (NCT04338581)
- Testing
- AMG 714, nbUVB phototherapy
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vitiligo
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
This is a prospective blinded within-subject randomized study to evaluate the application of Spray-On Skin™ Cells, prepared using the RECELL® Device for safe and effective repigmentation of ablated stable vitiligo lesions.
- Trial name
- NCT04547998
- Testing
- Control Intervention (UVB), Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)
- Where
- 12 sites in United States
- Volunteers
- 25 people
- Sponsor
- Avita Medical
Vitiligo
ERASE VITILIGO Early Repigmentation Approach for Stopping the Evolution of VITILIGO Prospective Multicentric Interventional Study With Blinded Evaluation
Vitiligo affects 1 to 2% of worldwide population and has a demonstrated impact on the quality of life. Optimal treatment of vitiligo requires to target the auto-immune inflammatory response (to halt the depigmentation process)…
- Trial name
- ERASE (NCT04843059)
- Testing
- The resident memory T-cell infiltrate in perilesional vitiligo skin
- Where
- 2 sites in France
- Volunteers
- 51 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Vitiligo
The Efficacy of Hand Narrow-Band Ultraviolet B (NBUVB) Versus Excilite Treatment in Vitiligo After Minigrafting on the Dorsal Hands
To assess over a 25-week period the efficacy of hand-foot narrow-band ultraviolet B light versus focal 308-nm light treatment in inducing the return of pigment in vitiligo after skin minigraft transplants to the backs of the…
- Trial name
- NCT00622180
- Testing
- NBUVB, Monochromacitc Excimer light
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Texas Southwestern Medical Center
Hair Problems
Hair Repigmentation During Cerebrolysin Therapy
Open-label histological study of scalp biopsies from patients undergoing treatment with Cerebrolysin as therapy for cerebrovascular disease.
- Trial name
- NCT05288465
- Testing
- Cerebrolysin
- Where
- Mexico
- Volunteers
- 5 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Vitiligo
Efficacy & Tolerance of Cosmetic Product RV5098A on Face Pigmentation Maintenance in Adult Vitiligo Patients.
Vitiligo is an autoimmune depigmentation disorder affecting 0.5 to 1% of the population worldwide. Vitiligo lesions are characterized by a progressive loss of pigmentation caused by the disappearance of functioning melanocytes in…
- Trial name
- NCT06446063
- Testing
- Test product, Control Product
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Vitiligo - Macular Depigmentation
0.005% Latanoprost Gel for Nonsegmental Vitiligo
Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation.
- Trial name
- NCT07016113
- Testing
- 0.005% latanoprost gel, 0.1% mometasone furoate cream
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- Universitas Padjadjaran
Vitiligo
Tissue-resident Memory T Cells Expression Among the Repigmentation Patterns Induced by NB-UVB Phototherapy in Vitiligo
Vitiligo is the most commonly acquired depigmentation disorder characterized by selective destruction of melanocytes resulting in well-circumscribed achromic macules.
- Trial name
- NCT05506995
- Where
- Mexico
- Volunteers
- 11 people
- Sponsor
- Universidad Autonoma de San Luis Potosí
Vitiligo
Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo
Vitiligo is a common chronic skin disease with 1-4% prevalence. It has a significant psychosocial impact on patients and society. Different treatment modalities with variable success rates are available.
- Trial name
- GB (NCT01006421)
- Testing
- GINGKO BILOBA
- Where
- Saudi Arabia
- Volunteers
- 160 people
- Sponsor
- King Saud University
Vitiligo
Repigmentation Patterns Induced by NB-UVB and Their Relationship With Melanocytic Migration in Vitiligo
Vitiligo is the most common acquired depigmented disorder of the skin characterized by destruction of melanocytes resulting in well-circumscribed achromic macules.
- Trial name
- UVBVIT (NCT02625012)
- Volunteers
- 30 people
- Sponsor
- Juan Pablo Castanedo-Cazares
Generalized Vitiligo
Comparing the Efficacy of Visible Light-Ultraviolet A1 Light Versus Narrowband-Ultraviolet B on Generalized Vitiligo
As part of this study, you may have a procedure called phototherapy which involves either VL-UVA or NB-UVB irradiation. NB-UVB phototherapy is not experimental in vitiligo, but use of VL-UVA1 phototherapy in vitiligo is.
- Trial name
- NCT05238077
- Testing
- Visible Light-Ultraviolet A Light or Narrowband-Ultraviolet B phototherapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Henry Ford Health System
Hyperlipidemias, Xerosis
Combined Effect of Acitretin and Narrow Band Ultraviolet B on Vitiligo Repigmentation
Since abnormal keratinocyte (KC) proliferation and differentiation as well as defective E cadherin expression were reported in vitiligo lesions, the investigators set to study the potential efficacy of combining Retinoids, which…
- Conditions
- Hyperlipidemias, Xerosis, Depression, Liver Diseases
- Trial name
- NCT04245319
- Testing
- Acitretin, Narrow band ultraviolet B
- Where
- Egypt
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cairo University
Patients With Active Non-segmental Vitiligo., Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05%
Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo
Rationale: Vitiligo vulgaris is a common acquired pigment disorder, which is characterised by the development of depigmented macules. It develops probably due to immunedestruction of melanocytes.
- Conditions
- Patients With Active Non-segmental Vitiligo., Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05%, Cream Compared to NB-UVB Alone in Patients With Non-segmental Vitiligo
- Trial name
- NCT01246921
- Testing
- Fluticasone proprionate 0.05% cream
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Vitiligo, Repigmentation
Topical Bimatoprost Solution 0.03%in Stable Vitiligo
Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population. Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors, and vitamin-D derivatives…
- Trial name
- NCT01202513
- Testing
- Bimatoprost 0.03% topical ophthalmic solution
- Volunteers
- 20 people
- Sponsor
- Gian Sagar Medical College and Hospital
Hyperpigmentation; Melanin, Laser-Induced Hyperpigmentation
Laser-Assisted Gingival Depigmentation
This randomized clinical trial evaluated the recurrence rates of physiological gingival pigments during 24 months follow-up and the patient perceptions after the ablative depigmentation using two laser wavelengths; Diode 940 nm…
- Trial name
- NCT04680806
- Testing
- Er,Cr:YSGG laser 2780 nm, Diode laser 940 nm
- Where
- Qatar
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Academy of Laser Dentistry - Gulf Laser Chapter
Photosensitivity Disorders
Conventional Microneedling vs Microneedling With 5-FU (MMP) for Idiopathic Guttate Hypomelanosis (IGH) Repigmentation
The purpose of this study is to determine whether 5-FU infusion (Microinfusion of Medicine Percutaneously - MMP) is effective for Idiopathic Guttate Hypomelanosis (IGH) repigmentation compared to conventional Microneedling.
- Trial name
- MMP (NCT02904564)
- Testing
- MMP with 5-FU, MMP with Saline infusion
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Clinica Dermatologica Arbache ltda
Vitiligo
A New Micrografting Technique for Vitiligo
This study evaluates micrografting using a harvesting and grafting process that has been designed by Momelan Technologies. The overall concept is to harvest several small pieces of skin, each measuring about 1.75 mm in diameter…
- Trial name
- NCT01262547
- Testing
- Dermabrasion-Micrografting, Dermabrasion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Vitiligo
Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo
Vitiligo is an autoimmune cutaneous disorder that destroys melanocytes leading to depigmented areas of skin. In the United States, vitiligo affects 1% of patients, causing not only changes in the color of skin, but also…
- Trial name
- NCT02191748
- Testing
- Needling, Triamcinolone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Rutgers, The State University of New Jersey
Vitiligo
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
This is a phase 2A clinical trial designed to test the pro-melanogenic and anti-inflammatory role of phosphodiesterase-4 inhibitors (PDE4i), alone and in combination with active narrow band UVB (NBUVB), in vitiligo lesions.
- Trial name
- NCT05298033
- Testing
- Crisaborole 2 % Topical Ointment, PF-07038124 0.01% topical ointment, NBUVB phototherapy
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Colorado, Denver
Vitiligo
Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO
Vitiligo is a depigmentation disorder affecting 0.5 to 2% of the general population. It is an acquired pigmentary disorder of the skin and mucous membranes that is characterized by circumscribed, depigmented macules and patches.
- Trial name
- Rapid Vitiligo (NCT03036995)
- Testing
- Apremilast
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Centre Hospitalier Universitaire de Nice